COMMUNIQUÉS West-GlobeNewswire
-
Brain Cancer Canada Awards The Dwayne Andrews Glioblastoma Research Grant to Tackle One of the Most Aggressive Brain Tumours and Unlock Immunotherapy Breakthroughs for Young Patients
21/05/2026 -
Medicana Strengthens Its International Sports Presence Through Expanded Healthcare Partnership with Fenerbahçe
21/05/2026 -
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
21/05/2026 -
Genvor Appoints Donald Kalkofen as Chief Financial Officer
21/05/2026 -
Nanobiotix annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
21/05/2026 -
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
21/05/2026 -
KOMO Biosciences Appoints Biologics Manufacturing Leader Darryl Sampey, PhD, to its Scientific Advisory Board
21/05/2026 -
SRx Health Solutions and EMJX Invest in Recent IPO and Commercial-Stage Pharmaceutical Company of Psychedelics, Optimi Health Corp. (OPTH)
21/05/2026 -
FLYTE ACTIVATES HIGH-FREQUENCY MEMORIAL DAY WEEKEND FLIGHT NETWORK TO CAPTURE SURGING NORTHEAST DEMAND
21/05/2026 -
Weight Loss Coaching vs. App-Only Programs: What Published Research Shows About Long-Term Outcomes
21/05/2026 -
Infex Therapeutics announces positive Phase IIa results for RESP-X in non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa
21/05/2026 -
Picard Medical / SynCardia Reports First Quarter 2026 Financial Results
21/05/2026 -
Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma
21/05/2026 -
Hemab Therapeutics Reports First Quarter 2026 Financial Results
21/05/2026 -
JavaTide Examined: 2026 Analysis of Ingredients Profile, Dosage Accuracy, and Metabolic Support Claims
21/05/2026 -
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
21/05/2026 -
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards
21/05/2026 -
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
21/05/2026 -
Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference
21/05/2026
Pages